Researchers at the Johns Hopkins School of Medicine studied the effects of psilocybin on treating anxiety and depression in patients with life-threatening cancer. Fifty-one patients received very low (1 or 3 mg/70 kg) or high dose (22 or 30 mg/70 kg) psilocybin and underwent a 6 month follow up. Patients in the high dose group saw large decreases in depressed mood and anxiety. They also had increases in quality of life, optimism, meaning of life, and a decrease in death anxiety.
Study Finds Long-lasting Positive Benefits for Cancer Patients Using Psilocybin
Researchers at Johns Hopkins University School of Medicine find psilocybin causes substantial and sustained decreases in anxiety and depression in patients with life-threatening cancer.